Current FDA labels document these patterns in detail: Wegovy (semaglutide) lists nausea (44% vs 16% placebo), vomiting (25% vs 6%), diarrhea (30% vs 16%), constipation (24% vs 11%), abdominal distension and eructation, with severe GI events in 4.1% versus 0.9% placebo.[2] Zepbound (tirzepatide) lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, and gastroesophageal reflux disease among common adverse reactions, with severe GI disease as a Warnings and Precautions item.[3] Both labels include postmarketing reports of ileus, severe constipation including fecal impaction, and acute kidney injury related to dehydration from severe GI symptoms
Women of childbearing age should use contraception while on tirzepatide and discontinue the medication at least 2 months before attempting conception to allow complete washout given the long half-life
The CuscoPuno Sun Route is a scenic land journey that connects Cusco with Puno, passing through Andean landscapes, lakes, and small communities
The endothelium is the thin layer of cells lining the inside of blood vessels
39,95 Prices may be subject to local taxes which are calculated during checkout Similar content being viewed by others References World Health Organization
Rantanen J, Khinast J